Galderma v. Lupin: Federal Circuit Affirms Six Tetracycline Patents (Case 24-1664)
Galderma Laboratories and TCD Royalty Sub successfully defended six US patents covering once-daily tetracycline formulations against generic challenger Lupin Inc. and Lupin Ltd. The Federal Circuit affirmed the lower court ruling across all six patents in 242 days, reinforcing the patent barrier around this branded drug portfolio.
Federal Circuit closes Lupin’s generic entry route on six tetracycline patents
Galderma Laboratories, L.P. and co-plaintiff TCD Royalty Sub, LLC filed this appeal on April 8, 2024 at the Court of Appeals for the Federal Circuit, asserting infringement of six US patents — US7749532B2, US8709478B2, US8470364B2, US8394406B2, US8206740B2, and US8394405B2 — all covering once-daily tetracycline formulations. The defendants, Lupin Inc. and Lupin Ltd., had challenged the patents as part of an ANDA-driven generic entry strategy targeting Galderma’s branded tetracycline product.
The Federal Circuit issued its ruling on December 6, 2024, affirming the lower court’s decision in full. The order states: ‘THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED.’ Affirmance at the Federal Circuit level means the appellate panel found no reversible legal or factual error in the district court’s analysis, leaving Galderma’s patent portfolio fully intact and Lupin’s ANDA pathway blocked on these claims.
The 242-day resolution is notably swift for a Federal Circuit patent appeal involving six patents, suggesting the panel may have found the issues well-settled or the district court record particularly complete. What drove Lupin’s decision to appeal rather than design around or settle, and whether further challenge routes — such as IPR petitions — remain open, is not disclosed in the public record. The affirmance strengthens Galderma’s exclusivity position in the once-daily tetracycline market.
Filing to Appeal Dismissed in 242 days
242 days — faster than the median Federal Circuit patent appeal, which typically runs 12–18 months
Federal Circuit affirms: what the ruling means for both parties
Affirmance means no reversible error found in the court below
When the Federal Circuit affirms, it signals that the appellate panel reviewed the district court’s legal conclusions de novo and its factual findings for clear error — and found neither. The lower court’s infringement analysis, claim construction, or validity determinations (as applicable) are now endorsed at the appellate level. The decision does not create new law but solidifies the existing ruling as the controlling outcome for this dispute.
No reversible errorGalderma’s six-patent portfolio survives appellate challenge intact
Affirmance is a strong outcome for Galderma and TCD Royalty Sub. All six asserted patents covering once-daily tetracycline formulations remain valid and enforceable as adjudicated. The ruling fortifies Galderma’s ability to block Lupin’s ANDA and likely deters other generic filers from pursuing identical litigation strategies. The exclusivity window on this formulation portfolio is now backed by Federal Circuit authority.
Patents enforceableLupin’s appellate avenue is exhausted; generic entry remains blocked
For Lupin Inc. and Lupin Ltd., the affirmance closes the direct litigation path at the Federal Circuit level. Petition for certiorari to the Supreme Court is theoretically available but rarely granted in ANDA patent cases. Lupin’s remaining strategic options — IPR petitions at the PTAB, design-around product development, or licensing negotiations — are not addressed by this ruling and remain unknown from the public record.
Generic entry blockedFederal Circuit endorsement raises the bar for future tetracycline generics
A Federal Circuit affirmance on a six-patent portfolio sends a clear signal to the broader generic pharmaceutical sector: the once-daily tetracycline claim landscape has survived rigorous appellate scrutiny. Competing generic filers targeting similar formulation patents should anticipate a higher evidentiary bar in district court and a less receptive appellate environment. Galderma’s licensing leverage is correspondingly strengthened.
Strengthened exclusivityFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | GALDERMALABORATORIES, L.P | Individual | Specialty pharma company — holder of once-daily tetracycline formulation patent portfolioSearch in Eureka ↗ |
| Co-Plaintiff | Tcd Royalty Sub, LLC | Company | Search in Eureka ↗ |
| Defendant | Lupin, Inc. | Company | Generic pharmaceutical manufacturer pursuing ANDA entry into the tetracycline marketSearch in Eureka ↗ |
| Co-Defendant | Lupin, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Andrew Cochran | Attorney | Counsel for GALDERMALABORATORIES, L.PSearch in Eureka ↗ |
| Plaintiff counsel | Gerald J. Flattmann Jr. | Attorney | Counsel for GALDERMALABORATORIES, L.PSearch in Eureka ↗ |
| Plaintiff law firm | Cahill Gordon & Reindel LLP | Law Firm | Representing GALDERMALABORATORIES, L.PSearch in Eureka ↗ |
| Defendant counsel | Adrianne C. Rose | Attorney | Counsel for Lupin, Inc.Search in Eureka ↗ |
| Defendant counsel | Joseph Thomas Jaros Esq. | Attorney | Counsel for Lupin, Inc.Search in Eureka ↗ |
| Defendant counsel | Katie Boda | Attorney | Counsel for Lupin, Inc.Search in Eureka ↗ |
| Defendant counsel | William A. Rakoczy | Attorney | Counsel for Lupin, Inc.Search in Eureka ↗ |
| Defendant law firm | Rakoczy, Molino, Mazzochi, Siwik LLP | Law Firm | Representing Lupin, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘ORDERED AND ADJUDGED: AFFIRMED’ — is unqualified affirmance covering the full scope of the district court’s ruling on all six asserted patents. In Federal Circuit ANDA appeals, affirmance without remand or modification indicates the panel found no claim construction error, no clear factual error on infringement or validity, and no legal deficiency in the lower court’s reasoning. For Galderma, this is the strongest possible appellate outcome: the patents survive with Federal Circuit endorsement, materially reinforcing their enforceability against future challengers.
US7749532B2 — once-daily tetracycline oral formulation portfolio
The six asserted patents — US7749532B2, US8709478B2, US8470364B2, US8394406B2, US8206740B2, and US8394405B2 — cover once-daily formulations of tetracycline-class antibiotics, including controlled-release oral dose forms and associated methods of use. Application dates span the mid-2000s through early 2010s, reflecting a sustained prosecution strategy that built layered claim coverage around a commercially significant formulation innovation in the dermatology and infectious disease therapeutic areas.
From a competitive standpoint, this portfolio represents a prototypical ‘formulation fence’ strategy: multiple patents with overlapping but distinct claims that collectively make it difficult for a generic entrant to design around any single patent without implicating others. The Federal Circuit’s affirmance validates this architecture at the highest domestic patent appellate level, making the portfolio a reference point for pharma companies building or challenging extended-release oral drug IP.
Should your team run an FTO against this tetracycline patent portfolio?
Any company developing generic, biosimilar, or novel once-daily tetracycline oral formulations — or extended-release antibiotic dose forms in adjacent classes — should treat this six-patent portfolio as a live freedom-to-operate risk. The Federal Circuit affirmance means these claims have survived both district court and appellate scrutiny, significantly raising the cost and uncertainty of any challenge. R&D teams reformulating tetracycline compounds for once-daily dosing are directly in scope.
PatSnap Eureka’s FTO Search Agent can map your formulation’s technical parameters against the claim language in all six patents simultaneously, flagging overlap and identifying whitespace. With Federal Circuit-endorsed claim scope now established, Eureka’s analysis tools help you assess design-around feasibility, monitor for continuation filings in this patent family, and track Galderma’s prosecution activity before you commit to a development pathway.
Run a freedom-to-operate analysis on US7749532B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit ANDA patent appeals in pharmaceutical formulations
Cases involving Federal Circuit review of multi-patent ANDA challenges in oral drug formulation — the same court and technology context as Galderma v. Lupin.
What this case signals for the pharmaceutical formulation IP landscape
A Federal Circuit affirmance across six ANDA-challenged patents is a material data point for any company competing in the tetracycline or extended-release formulation space.
Multi-patent formulation portfolios create durable appellate barriers
Galderma’s strategy of asserting six patents across overlapping formulation claims proved resilient at both district and appellate levels. Companies designing generic entry strategies should assume that Federal Circuit-affirmed multi-patent portfolios require either IPR success on multiple fronts or a credible design-around — not just a single invalidity argument.
ANDA challengers face compounding risk after Federal Circuit loss
Lupin’s failure at appeal leaves its ANDA blocked with no clear litigation path remaining. Generic filers in tetracycline or related oral solid dose formulations should audit their paragraph IV certifications against this affirmed claim scope before filing, as the precedential weight of this ruling may influence district court outcomes in parallel cases.
L.P v Lupin — key questions answered
The Federal Circuit affirmed the lower court’s ruling in full on December 6, 2024. All six Galderma patents covering once-daily tetracycline formulations (US7749532B2, US8709478B2, US8470364B2, US8394406B2, US8206740B2, US8394405B2) were upheld, blocking Lupin’s ANDA-based generic entry strategy. The court found no reversible error in the district court’s analysis.
Galderma Laboratories and TCD Royalty Sub asserted six US patents: US7749532B2, US8709478B2, US8470364B2, US8394406B2, US8206740B2, and US8394405B2. All six cover once-daily formulations of tetracycline-class compounds, collectively forming a layered formulation patent portfolio that the Federal Circuit affirmed in its entirety.
Affirmance means Lupin’s ANDA remains blocked by all six patents with no direct appellate remedy remaining. Lupin could theoretically petition the Supreme Court for certiorari, pursue inter partes review at the PTAB on grounds not already litigated, or attempt a design-around formulation. None of these options are addressed in the public record of this case.
TCD Royalty Sub, LLC appears as co-plaintiff alongside Galderma Laboratories, L.P. Its role as a royalty sub-entity suggests it holds an ownership or licensing interest in one or more of the six asserted patents. This structure is consistent with patent monetisation arrangements common in pharmaceutical IP portfolios, though the specific terms of TCD’s interest are not disclosed in the public record.
The appeal was filed on April 8, 2024 and decided on December 6, 2024 — a duration of 242 days. This is notably faster than the typical Federal Circuit patent appeal timeline, which commonly runs 12 to 18 months or longer for cases involving multiple patents. The swift resolution may suggest the panel considered the legal issues relatively well-defined based on the district court record.
PatSnap Eureka searches patents and litigation data to answer instantly.